Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor

Esperite (voorheen Cryo Save)« Terug naar discussie overzicht

NEWS : Esperite upgrade Tranquility

257 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 13 »» | Laatste | Omlaag ↓
  1. stormvogel 19 mei 2015 10:05
    Tranquility to the most complete CE-IVD fetal DNA NIPT test.

    TRANQUILITY tops the trisomies detection market by combining the technologies of IONA and InKaryo, the recently acquired company now part of the ESPERITE group. TRANQUILITY's entire testing process for trisomies (sample collection, preparation, sequencing, bioinformatics analysis and report) is compliant with the European In Vitro Diagnostics Medical Devices Directive 98/79/EC and has been certified by an independent body -UL International. TRANQUILITY, the only CE-IVD certified genetic test for trisomies 21, 18 and 13 that provides, sexual aneuploidies, microdeletions and fetal sex detection, now ready for mass market.

    Succesfully launched in several countries, Tranquility already contributes to the positive trend of growth that GENOMA is recording in the Group's key markets: Spain, Italy, Hungary, Serbia, etc.

    The NIPT test is more sensitive and specific than the current combined test, providing accurate and reliable results to pregnant women. The benefits of NIPT are a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result. This further reduces the need for unnecessary invasive follow-up tests and the associated anxiety and stress.

    Genoma targets a population of 10 million newborns per year in Europe and The Middle East.

    www.stockhouse.com/news/press-release...

    Collaboration agreement with Premaitha Health for provision NIPT in Europe.

    GENOMA signed an agreement with Premaitha Health plc ("Premaitha", AIM: NIPT) under which GENOMA will have the right to use Premaitha's CE-IVD IONA® test for its non-invasive prenatal testing (NIPT) TRANQUILITY®. Access to Premaitha's test will allow GENOMA to apply the CE-IVD marking to its NIPT for trisomies 21, 18 and 13.
  2. [verwijderd] 19 mei 2015 11:58
    Van dit soort stukjes wordt ik echt blij. Er zit nog veel meer in het vat voor Esperite beleggers:

    Frédéric Amar, Chief Executive officer, commented:

    "Esperite is best-positioned to capitalize on the current confluence of demographic and economic indicators: higher purchasing power, augmented healthcare needs and a health-conscious aging population. Esperite elaborates and makes its mass products affordable to society and national health systems, profiting from the incremental processing and sequencing capacity to produce higher throughput at lower costs.

    Esperite combines cutting-edge technologies and scientific knowledge on its automated processes to deliver the vital genetic information that enables preventive and personalized medicine. Esperite's products and services empower doctors and families to take a proactive and most effective approach to their health".

    ESPERITE WILL DISCLOSE MORE ON ITS STRATEGY DURING THE AGM CONVENED ON JUNE 17TH 2015 IN AMSTERDAM.
257 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 13 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.